Verition Fund Management
LRMR icon

Verition Fund Management’s Larimar Therapeutics LRMR Stock Holding History

Verition Fund Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-567,683
Closed -$2.16M – 3021
2025
Q4 		$2.16M Hold
567,683
– – 0.01% 1537
2025
Q3 		$1.83M Hold
567,683
– – 0.01% 2051
2025
Q2 		$1.64M Hold
567,683
– – 0.01% 2099
2025
Q1 		$1.22M Sell
567,683
-470,065
-45% -$1.49M 0.01% 1967
2024
Q4 		$4.02M Sell
1,037,748
-124,002
-11% -$819K 0.02% 1045
2024
Q3 		$7.61M Sell
1,161,750
-432,400
-27% -$3.48M 0.04% 561
2024
Q2 		$11.6M Buy
1,594,150
+92,531
+6% +$709K 0.06% 293
2024
Q1 		$11.4M Sell
1,501,619
-1,309,512
-47% -$10.2M 0.08% 288
2023
Q4 		$12.8M Sell
2,811,131
-89,407
-3% -$302K 0.1% 182
2023
Q3 		$11.5M Buy
2,900,538
+183,825
+7% +$695K 0.13% 180
2023
Q2 		$8.5M Buy
2,716,713
+777,891
+40% +$3.17M 0.11% 244
2023
Q1 		$8.78M Buy
1,938,822
+462,598
+31% +$2.42M 0.12% 221
2022
Q4 		$6.1M Buy
1,476,224
+84,888
+6% +$290K 0.1% 263
2022
Q3 		$4.45M Buy
1,391,336
+987,446
+244% +$2.47M 0.05% 476
2022
Q2 		$792K Sell
403,890
-20,709
-5% -$61.2K 0.02% 1161
2022
Q1 		$1.72M Buy
424,599
+188,764
+80% +$1.24M 0.02% 1080
2021
Q4 		$2.54M Buy
235,835
+156,179
+196% +$1.74M 0.02% 717
2021
Q3 		$918K Sell
79,656
-165,019
-67% -$1.98M 0.01% 966
2021
Q2 		$2.4M Buy
244,675
+15,374
+7% +$174K 0.02% 465
2021
Q1 		$3.35M Buy
229,301
+106,194
+86% +$1.93M 0.04% 281
2020
Q4 		$2.64M Buy
123,107
+71,107
+137% +$1.42M 0.02% 320
2020
Q3 		$789K Buy
+52,000
New +$658K 0.02% 433

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Verition Fund Management's LRMR Position: Q1 2026 in Review

Verition Fund Management sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 567,683 shares — an estimated $2.16M sold.

Verition Fund Management first reported a position in LRMR in Q3 2020 and held it in 22 quarters. The position peaked at $12.8M in Q4 2023. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Verition Fund Management reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 567,683 Larimar Therapeutics shares in Q1 2026, an estimated $2.16M.
  • Verition Fund Management first reported a position in Larimar Therapeutics in Q3 2020 and held it in 22 quarters.
  • Verition Fund Management's Larimar Therapeutics position peaked at $12.8M in Q4 2023.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.